Osellame et al. 15 (La Trobe University, Melbourne, VIC, Australia) developed an antibody that targets the TWEAK receptor Fn14, on the tumour surface, which is able to abrogate symptoms of cachexia in syngeneic mouse models. Here, TNFRSF12A is linked to neoplasm.